DK0410389T3 - Indolocarbazol og dens anvendelse - Google Patents

Indolocarbazol og dens anvendelse

Info

Publication number
DK0410389T3
DK0410389T3 DK90114182.0T DK90114182T DK0410389T3 DK 0410389 T3 DK0410389 T3 DK 0410389T3 DK 90114182 T DK90114182 T DK 90114182T DK 0410389 T3 DK0410389 T3 DK 0410389T3
Authority
DK
Denmark
Prior art keywords
tetrahydro
diseases
benzodiazocine
diindolo
pyrrolo
Prior art date
Application number
DK90114182.0T
Other languages
English (en)
Inventor
Johannes Dr Hartenstein
Juergen Dr Kleinschroth
Claus Dr Rudolph
Christoph Dr Schaechtele
Original Assignee
Goedecke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goedecke Ag filed Critical Goedecke Ag
Application granted granted Critical
Publication of DK0410389T3 publication Critical patent/DK0410389T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK90114182.0T 1989-07-25 1990-07-24 Indolocarbazol og dens anvendelse DK0410389T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3924538A DE3924538A1 (de) 1989-07-25 1989-07-25 Indolocarbazol und dessen verwendung

Publications (1)

Publication Number Publication Date
DK0410389T3 true DK0410389T3 (da) 1995-07-24

Family

ID=6385761

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90114182.0T DK0410389T3 (da) 1989-07-25 1990-07-24 Indolocarbazol og dens anvendelse

Country Status (7)

Country Link
US (1) US5043335A (da)
EP (1) EP0410389B1 (da)
JP (2) JP3140453B2 (da)
AT (1) ATE119906T1 (da)
DE (2) DE3924538A1 (da)
DK (1) DK0410389T3 (da)
ES (1) ES2068953T3 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478813A (en) * 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
EP0580812A1 (en) * 1991-04-11 1994-02-02 Schering Corporation Anti-tumor and anti-psoriatic agents
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2123096A1 (en) * 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
EP0630242B1 (en) * 1992-03-20 1999-01-20 The Wellcome Foundation Limited Further indole derivatives with antiviral activity
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435318D1 (de) 1993-01-28 2010-12-09 Boston Scient Ltd Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
KR100201343B1 (ko) * 1993-05-28 1999-06-15 바바라 에스 쉴버그 인돌로카르바졸 유도체들의 전립선의 병적상태치료에의 용도
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
YU49200B (sh) * 1993-12-07 2004-09-03 Eli Lilly And Company Inhibitori proteinske kinaze c
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5804564A (en) * 1994-05-09 1998-09-08 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
JP2000514420A (ja) 1996-06-25 2000-10-31 セファロン・インコーポレイテッド 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用
ATE278397T1 (de) 1997-03-31 2004-10-15 Boston Scient Ltd Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
JP2002526450A (ja) * 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
US6472385B1 (en) * 1999-08-09 2002-10-29 Trustees Of Darmouth College Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
BR0208322A (pt) 2001-03-22 2004-10-13 Bristol Myers Squibb Co Derivados de açúcar citotóxixo seletivo da topoisomerase i de indolopirrolocarbazóis
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
CN100529101C (zh) * 2003-03-03 2009-08-19 弗洛里安·朗 用作诊断和治疗靶的sgk1
JP5211464B2 (ja) 2006-10-20 2013-06-12 東京エレクトロン株式会社 被処理体の酸化装置
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen

Also Published As

Publication number Publication date
ES2068953T3 (es) 1995-05-01
EP0410389A1 (de) 1991-01-30
DE59008696D1 (de) 1995-04-20
JPH0358990A (ja) 1991-03-14
ATE119906T1 (de) 1995-04-15
JP2001106691A (ja) 2001-04-17
JP3140453B2 (ja) 2001-03-05
US5043335A (en) 1991-08-27
EP0410389B1 (de) 1995-03-15
DE3924538A1 (de) 1991-01-31

Similar Documents

Publication Publication Date Title
DK0410389T3 (da) Indolocarbazol og dens anvendelse
GR3001738T3 (en) Pyrrolocarbazole derivatives, processes for their preparation and their use as medicaments
AP9701146A0 (en) Fused bicyclic pyrimidine derivatives.
ZA895090B (en) Novel benzopyran derivatives,processes for their preparation and their use and preparations containing the compounds
HUT71130A (en) Condensed indole derivatives of protein kinase c inhibitor activity, process for preparing them and pharmaceutical compositions containing them
IL99525A0 (en) Fused ring analogs of nitrogen containing nonaromatic heterocycles
BG102879A (en) Carbolin derivatives
DK11391D0 (da) Alkoxy-4(1h)-pyridonderivater og farmakologisk acceptable salte deraf, deres fremstilling og anvendelse
PT84899A (en) Process for the preparation of pharmaceutical compositions containing ?-phenyl-1,2-benzisoselenazol-3(2h)-one for the treatment of skin diseases
HUP9902805A3 (en) Use of macrocyclic bis(indolyl)-maleimide derivatives for the preparation of pharmaceutical compositions treating ocular diseases
GR3003452T3 (en) Indolocarbazole derivatives, processes for their preparation and their use as medicaments
LTIP903A (en) Preparation process of solid pharmaceutical forms and such forms
GR3020866T3 (en) Indolocarbazole derivatives, processes for their preparation and their use
DK440287D0 (da) 9-deazaguaniner, farmaceutiske kompositioner indeholdende forbindelserne, og fremgangsmaade til forbindelsernes fremstilling
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
ES2001875A6 (es) Procedimiento para preparar nuevos derivados de aminoacidos
IL79910A0 (en) Tricyclic compounds,process for the preparation thereof and pharmaceutical compositions containing the same
CA2127763A1 (en) Alkaloids from Mappia Foetida, the Use Thereof and Formulations Containing Them
ZA787215B (en) New amino derivatives of pyrazolo(1,5-a)s.triazine,processes for their preparation and their therapeutic applications
HUT39180A (en) Process for preparing 4-oxo-pyrido (2,3-d) pyrimidine-derivatives and pharmaceuticals comprising such compounds
DK0401093T3 (da) Hidtil ukendte pyrrolidonderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende disse
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
GB2016002B (en) Amino derivatives of pyrazolo(1,5-a)s triazine
OA09487A (fr) "Procédé de préparation de nouvelles pyrrolo (1,2-a)thiéno (3,2-f) diazépines(1,4)".
ES2062351T3 (es) Derivados de triazolo (4,5-c) piridina anticonvulsivos.